Trevor, Anthony J.; Katzung, Bertram G. (2003). 《Pharmacology》. New York: Lange Medical Books/McGraw-Hill, Medical Publishing Division. 43쪽. ISBN978-0-07-139930-2.
Conti JB, Belardinelli L, Utterback DB, Curtis AB (March 1995). “Endogenous adenosine is an antiarrhythmic agent”. 《Circulation》 91 (6): 1761–67. doi:10.1161/01.cir.91.6.1761. PMID7882485.
Brugada P (July 2000). “Magnesium: an antiarrhythmic drug, but only against very specific arrhythmias”. 《Eur. Heart J.》 21 (14): 1116. doi:10.1053/euhj.2000.2142. PMID10924290.
Hoshino K, Ogawa K, Hishitani T, Isobe T, Eto Y (October 2004). “Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome”. 《J Am Coll Nutr》 23 (5): 497S–500S. doi:10.1080/07315724.2004.10719388. PMID15466950. S2CID30146333.
Hoshino K, Ogawa K, Hishitani T, Isobe T, Etoh Y (April 2006). “Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome”. 《Pediatr Int》 48 (2): 112–17. doi:10.1111/j.1442-200X.2006.02177.x. PMID16635167. S2CID24904388.
Lindberg JS, Zobitz MM, Poindexter JR, Pak CY (1990). “Magnesium bioavailability from magnesium citrate and magnesium oxide”. 《Journal of the American College of Nutrition》 9 (1): 48–55. doi:10.1080/07315724.1990.10720349. PMID2407766.
Damato, Anthony N. (1969년 7월 1일). “Diphenylhydantoin: Pharmacological and clinical use”. 《Progress in Cardiovascular Diseases》 12 (1): 1–15. doi:10.1016/0033-0620(69)90032-2. PMID5807584.
Conti JB, Belardinelli L, Utterback DB, Curtis AB (March 1995). “Endogenous adenosine is an antiarrhythmic agent”. 《Circulation》 91 (6): 1761–67. doi:10.1161/01.cir.91.6.1761. PMID7882485.
Brugada P (July 2000). “Magnesium: an antiarrhythmic drug, but only against very specific arrhythmias”. 《Eur. Heart J.》 21 (14): 1116. doi:10.1053/euhj.2000.2142. PMID10924290.
Hoshino K, Ogawa K, Hishitani T, Isobe T, Eto Y (October 2004). “Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome”. 《J Am Coll Nutr》 23 (5): 497S–500S. doi:10.1080/07315724.2004.10719388. PMID15466950. S2CID30146333.
Hoshino K, Ogawa K, Hishitani T, Isobe T, Etoh Y (April 2006). “Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome”. 《Pediatr Int》 48 (2): 112–17. doi:10.1111/j.1442-200X.2006.02177.x. PMID16635167. S2CID24904388.
Lindberg JS, Zobitz MM, Poindexter JR, Pak CY (1990). “Magnesium bioavailability from magnesium citrate and magnesium oxide”. 《Journal of the American College of Nutrition》 9 (1): 48–55. doi:10.1080/07315724.1990.10720349. PMID2407766.
Charlier, R; Deltour, G; Baudine, A; Chaillet, F (November 1968). “Pharmacology of amiodarone, and anti-anginal drug with a new biological profile.”. 《Arzneimittel-Forschung》 18 (11): 1408–17. PMID5755904.
Damato, Anthony N. (1969년 7월 1일). “Diphenylhydantoin: Pharmacological and clinical use”. 《Progress in Cardiovascular Diseases》 12 (1): 1–15. doi:10.1016/0033-0620(69)90032-2. PMID5807584.
“The 'Sicilian Gambit'. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology”. 《Eur. Heart J.》 12 (10): 1112–31. October 1991. PMID1723682.
Hoshino K, Ogawa K, Hishitani T, Isobe T, Eto Y (October 2004). “Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome”. 《J Am Coll Nutr》 23 (5): 497S–500S. doi:10.1080/07315724.2004.10719388. PMID15466950. S2CID30146333.
Hoshino K, Ogawa K, Hishitani T, Isobe T, Etoh Y (April 2006). “Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome”. 《Pediatr Int》 48 (2): 112–17. doi:10.1111/j.1442-200X.2006.02177.x. PMID16635167. S2CID24904388.